Bristol-Myers Squibb Company (BMY)

57.50
0.37 0.64
NYSE : Health Care
Prev Close 57.87
Open 57.33
Day Low/High 56.94 / 57.69
52 Wk Low/High 46.01 / 60.45
Volume 7.88M
Avg Volume 7.35M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 94.49B
EPS 2.70
P/E Ratio 21.03
Div & Yield 1.56 (2.70%)

Latest News

Cramer: Investors Can't Get Enough of Bristol-Myers Despite Latest Drug Setback

Cramer: Investors Can't Get Enough of Bristol-Myers Despite Latest Drug Setback

Despite a Phase 3 stumble, BMY stock is holding up.

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis

Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.

Bristol-Myers Squibb Stock Falls as Kidney Cancer Drug Fails

Bristol-Myers Squibb Stock Falls as Kidney Cancer Drug Fails

Late stage trials failed to show significant statistical efficacy.

Bristol-Myers Squibb Announces Topline Results From CheckMate -214, A Phase 3 Study Of Opdivo In Combination With Yervoy In Intermediate And Poor-Risk Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Bristol-Myers Squibb Announces Topline Results From CheckMate -214, A Phase 3 Study Of Opdivo In Combination With Yervoy In Intermediate And Poor-Risk Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and...

Doesn't Take Long to Be Bullish

Russell 2000 has best day since June 1 and transports bounce.

Capturing Profits on AIG

Capturing Profits on AIG

Let's roll with the sure thing and not wait for expiry.

These Biotech Stocks are BOOMING

These Biotech Stocks are BOOMING

Perrigo leading the charge.

In Good Company on Bristol-Myers

In Good Company on Bristol-Myers

Move over, Helene, I'm getting in on what appears to be a breakout.

Bristol-Myers Squibb To Acquire IFM Therapeutics To Strengthen Oncology Pipeline Focus On Innate Immunity

Bristol-Myers Squibb To Acquire IFM Therapeutics To Strengthen Oncology Pipeline Focus On Innate Immunity

Bristol-Myers Squibb Company (NYSE:BMY) and IFM Therapeutics (IFM) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital...

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

One of the hottest biotech stocks of the last month is selling off.

Cramer: Why I Spent My Weekend Defending the Bull Market

Cramer: Why I Spent My Weekend Defending the Bull Market

I've heard all of the bearish arguments, but I don't believe them.

Pfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff

Pfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff

A glimpse of what to expect during Tuesday's pre-market.

Clovis Sell-Off May Be Overdone

Clovis Sell-Off May Be Overdone

Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.

Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why

Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why

Several stocks spent Monday's trading session in the red, and here's why.

With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too

With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too

The results from a clinical trial of AstraZeneca's lung cancer treatment increase uncertainty about Bristol-Myers' immuno-oncology franchise, according to BMO analyst Alex Arfaei.

AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers

AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers

Shares lost more than 16% in London trading

Nasdaq Tumbles as Tech Takes a Turn Lower

Nasdaq Tumbles as Tech Takes a Turn Lower

The Nasdaq tumbles and the S&P 500 slides. The Dow rises slightly.

Wall Street Trades at Records as Facebook Rallies

Wall Street Trades at Records as Facebook Rallies

Stocks are higher.

Stock Futures Power Higher on Earnings Beat From Facebook

Stock Futures Power Higher on Earnings Beat From Facebook

Stock futures are higher.

Facebook on Fire - 5 Things You Must Know Before the Market Opens Thursday

Facebook on Fire - 5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures point higher after Facebook shares jump.

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2017 which were highlighted by strong sales for key products Opdivo and Eliquis and regulatory approvals for Opdivo, the...

Bristol-Myers Squibb's ORENCIA® (abatacept) Receives Second European Commission Approval In Less Than A Year - New Approval For Treatment Of Active Psoriatic Arthritis (PsA)1

Bristol-Myers Squibb's ORENCIA® (abatacept) Receives Second European Commission Approval In Less Than A Year - New Approval For Treatment Of Active Psoriatic Arthritis (PsA)1

Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission (EC) has approved ORENCIA alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis (PsA) in adult...

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

Amazon Snags Former Box Executive of Health In Pursuit of the Medical Industry

Amazon Snags Former Box Executive of Health In Pursuit of the Medical Industry

Amazon has been reinforcing its HIPAA-compliant offerings so that health-care providers and insurers can save and transfer customer data.